AR113022A1 - Anticuerpo anti-pacap - Google Patents

Anticuerpo anti-pacap

Info

Publication number
AR113022A1
AR113022A1 ARP180102618A ARP180102618A AR113022A1 AR 113022 A1 AR113022 A1 AR 113022A1 AR P180102618 A ARP180102618 A AR P180102618A AR P180102618 A ARP180102618 A AR P180102618A AR 113022 A1 AR113022 A1 AR 113022A1
Authority
AR
Argentina
Prior art keywords
antibodies
pacap antibody
pacap
migraine
compositions
Prior art date
Application number
ARP180102618A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR113022A1 publication Critical patent/AR113022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente descripción se refiere a anticuerpos contra el péptido activador de la adenilato ciclasa de la pituitaria (PACAP), composiciones que comprenden tales anticuerpos y métodos para usar tales anticuerpos para el tratamiento del dolor incluyendo cefalea y/o migraña.
ARP180102618A 2017-09-29 2018-09-13 Anticuerpo anti-pacap AR113022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
AR113022A1 true AR113022A1 (es) 2020-01-15

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102618A AR113022A1 (es) 2017-09-29 2018-09-13 Anticuerpo anti-pacap

Country Status (25)

Country Link
US (3) US10519225B2 (es)
EP (1) EP3688035A1 (es)
JP (2) JP6952888B2 (es)
KR (1) KR102453573B1 (es)
CN (1) CN111164105B (es)
AR (1) AR113022A1 (es)
AU (1) AU2018341959B2 (es)
BR (1) BR112020003628A2 (es)
CA (1) CA3077304C (es)
CL (1) CL2020000705A1 (es)
CO (1) CO2020002170A2 (es)
CR (1) CR20200127A (es)
DO (1) DOP2020000060A (es)
EA (1) EA202090563A1 (es)
EC (1) ECSP20020293A (es)
IL (1) IL273529A (es)
JO (1) JOP20200069A1 (es)
MA (1) MA50654A (es)
MX (1) MX2020003563A (es)
NZ (1) NZ762312A (es)
PE (1) PE20201494A1 (es)
SG (1) SG11202002572YA (es)
TW (1) TWI701260B (es)
WO (1) WO2019067293A1 (es)
ZA (1) ZA202001058B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283169A4 (en) 2015-04-16 2019-03-20 Alder Biopharmaceuticals, Inc. USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR THE TREATMENT, PREVENTION OR INHIBITION OF PHOTOPHOBY
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014786A1 (en) * 1990-03-17 1991-10-03 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
EP1583550A2 (en) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
WO2014144632A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
EP3283169A4 (en) * 2015-04-16 2019-03-20 Alder Biopharmaceuticals, Inc. USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR THE TREATMENT, PREVENTION OR INHIBITION OF PHOTOPHOBY
EP3390447A1 (en) * 2015-12-15 2018-10-24 Amgen Inc. Pacap antibodies and uses thereof
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
KR20200040881A (ko) 2020-04-20
EP3688035A1 (en) 2020-08-05
MA50654A (fr) 2020-08-05
JP7221352B2 (ja) 2023-02-13
PE20201494A1 (es) 2020-12-29
IL273529A (en) 2020-05-31
SG11202002572YA (en) 2020-04-29
MX2020003563A (es) 2020-08-03
US10954292B2 (en) 2021-03-23
TWI701260B (zh) 2020-08-11
AU2018341959A1 (en) 2020-03-05
TW201920280A (zh) 2019-06-01
US20200131256A1 (en) 2020-04-30
CL2020000705A1 (es) 2020-09-11
US20190100579A1 (en) 2019-04-04
US10519225B2 (en) 2019-12-31
KR102453573B1 (ko) 2022-10-12
JP2022000049A (ja) 2022-01-04
CN111164105A (zh) 2020-05-15
ECSP20020293A (es) 2020-06-30
US20210171616A1 (en) 2021-06-10
ZA202001058B (en) 2022-06-29
NZ762312A (en) 2022-11-25
AU2018341959B2 (en) 2021-11-25
EA202090563A1 (ru) 2020-06-24
JP2020535167A (ja) 2020-12-03
DOP2020000060A (es) 2020-08-15
WO2019067293A1 (en) 2019-04-04
BR112020003628A2 (pt) 2020-09-01
JP6952888B2 (ja) 2021-10-27
CO2020002170A2 (es) 2020-04-01
CA3077304A1 (en) 2019-04-04
CA3077304C (en) 2023-08-01
CR20200127A (es) 2020-04-08
CN111164105B (zh) 2023-07-04
JOP20200069A1 (ar) 2020-04-28

Similar Documents

Publication Publication Date Title
ECSP20020293A (es) Anticuerpo anti-pacap
DOP2017000303A (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112018011154A2 (pt) dispersões sólidas compreendendo um estimulador de sgc
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
PH12017501205A1 (en) Glucagon derivatives
BR112017004739A2 (pt) ligantes de hormônio folículo estimulante, complexo de ligante e gonadotrofina, uso de um ligante, e composição farmacêutica
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
CL2020001846A1 (es) Anticuerpos pac1 y sus usos
EA201500830A1 (ru) Противогрибковая композиция для наружного применения для лечения онихомикоза
BR112018006170B8 (pt) Método e composição para clareamento de pele usando um extrato de cultura celular de earliella scabrosa e seu uso
CO2019005540A2 (es) Aislados modificados de streptomyces fungicidicus y su uso
BR112017010958A2 (pt) composição cosmética de alto desempenho com poliorganossiloxano e um dipeptídeo
CL2019001924A1 (es) Composición fungicida efectiva contra alternaria en cítricos. (divisional solicitud 201701815)
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
UY36742A (es) Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona
EA201992616A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ СНИЖЕНИЯ ИММУНОГЕННОСТИ ХИМЕРНЫХ РЕЦЕПТОРОВ Notch
AR112992A1 (es) Concentrado de proteína de soja hidrolizado en condición de baja humedad y método de preparación del mismo